Thesis: Schrödinger is the one Tier-2 AI-bio platform with a real business under the lottery ticket — recurring, high-margin software licensed to pharma, plus a wholly-owned pipeline, plus a venture equity portfolio. That's a sum-of-parts at a low EV, not a pure cash-burn option like ABCL/GENB. The software is the floor; the pipeline and stakes are the upside.

Setup (tape 2026-06-04, code-computed summary)

$15.80, RSI 71, +22% 30d, +20% 3m, −43% from 52wk high (~$28); weak-up. Deeply off its high but bounced hard recently — RSI 71 is hot short-term, so the immediate entry isn't ideal even though it's cheap vs its range.

• Entry zone: ~$13–15 (let the +20% pop cool / a pullback toward the base). Don't chase RSI 71.
• Stop: ~$11 (loses the recovery base = the re-rate thesis stalls).
• Targets: base $22–28 (back toward the prior high) on software growth + pipeline/Novartis milestones; a sum-of-parts (software biz + ~$0.40B cash + equity stakes + pipeline) arguably underpins more than the current ~$0.72B EV, so the floor is firmer than the GAAP losses suggest.

What it is — three businesses in one (Massive company)

850 employees, $1.12B mcap. (1) Software — physics-based molecular-simulation platform (free-energy perturbation, etc.) licensed to ~every major pharma + biotech; recurring, high-margin, the moat. (2) Drug discovery — its own wholly-owned pipeline + collaboration milestones/royalties (a multi-year, up-to-$2.5B Novartis software-and-discovery deal is the marquee validation). (3) Equity stakes — co-founded biotechs (Nimbus, Morphic — acquired by Lilly, etc.); a venture portfolio that's not marked to market on the balance sheet, i.e. hidden value. This software-moat-plus-optionality structure is what separates SDGR from the pure-burn AI-bio names.

The financials: a real moat, but lumpy and still burning (Massive balance/income, through Q1 2026-03-31)

The read: unlike ABCL/GENB (options on a platform that doesn't yet sell much), SDGR already sells a recurring software product to the whole industry — that's a durable revenue floor and a real moat. But it chooses to plow cash into its own pipeline, so it runs GAAP losses and lumpy quarters. You're buying a quality software asset + free options (pipeline, equity stakes) at a sub-$0.7B EV — the highest-quality way to own the AI-drug-discovery layer, with the trade-off that the P&L is noisy and the pipeline is binary.

Why it's here / where it sits in the lane

Tier-2 (app-layer platform), but the quality leader of that tier — it's −43% off its high (de-rated with the whole AI-bio/biotech complex) yet has the only real recurring-revenue moat in the group. As the funding gate opens, the app-layer re-rates; SDGR re-rates with less binary risk than the cash-burn names because the software business carries it. Within the app-layer barbell (ABCL = cash-backed/bad-entry, GENB = below-IPO/runway-clock), SDGR is the quality third leg — the one you'd hold for the moat rather than the option.

Watch-fors / catalysts

• Software revenue growth + ACV (annual contract value) — the moat's health; the number that should compound through the cycle independent of milestones.
• Pipeline readouts (wholly-owned programs) + new/expanded pharma deals (à la Novartis) — the optionality leg.
• Equity-stake monetizations (an M&A of a co-founded biotech, like Morphic→Lilly) — episodic hidden-value crystallization.
• Cash-burn discipline — zero debt + ~$0.40B liquidity, but ~$150–200M/yr burn means watch runway and any raise.
• Risk: lumpy quarters cause sentiment whipsaws; a soft software-renewal cycle or a pipeline failure hits both legs; at RSI 71 the near-term entry is extended.

Sources

• Tape: code-computed summary biotech-capital-cycle (2026-06-04).
• Financials: Massive company/balance/income for SDGR (statements through Q1 2026-03-31; the lumpy-Q4 pattern + net-positive Q4'25 are in the data; saved to data/stocks/SDGR/massive/). Ratios premium-gated.
• Validation: up-to-$2.5B Novartis software/discovery deal (2025); Morphic (co-founded) acquired by Lilly — equity-stake precedent.
• Lane context: perspective biotech-capital-cycle (Tier-2 app-layer, quality leader; completes the ABCL/GENB/SDGR app-layer set).
• Open follow-ups: pull the software-vs-drug-discovery revenue split + ACV and the equity-stake carrying values from the 10-Q/10-K (massive:filings) to firm the sum-of-parts; analyst mean target.